Israel-based technology company OncoHost announced on Wednesday that it has partnered with European cancer centre Gustave Roussy to identify non-invasive biomarkers for immune-related adverse events (irAEs) in patients undergoing immunotherapy.

Immunotherapy harnesses the immune system to fight tumours. However, it can trigger severe and sometimes life-threatening autoimmune side effects, especially in combination regimens. Predicting which patients are at risk of developing these toxicities remains a significant challenge.

The PREMIS study, promoted by Gustave Roussy, is aimed at identifying predictive biomarkers for irAEs in patients receiving immunotherapy. As part of this broader effort, OncoHost is partnering with Gustave Roussy to further validate its PROphetirAE test -- an advanced tool that uses AI and biomarker analysis to assess patients' risk of developing irAEs. This collaboration supports the study's goal of enabling personalised treatment strategies that minimise toxicities and improve therapeutic outcomes.

The initiative designed to identify biomarkers that can predict the onset of irAEs has enrolled 1,000 cancer patients receiving immunotherapy with monoclonal antibodies (anti-PD-1, anti-PD-L1, anti-CTLA4 and combinations). This unique study is built within a dedicated pharmacovigilance department, allowing for the systematic collection of key clinical data and comprehensive characterisation of irAEs.